home / stock / vtgn / vtgn news

VTGN News and Press, VistaGen Therapeutics Inc. From 12/10/19

Stock Information
Company Name: VistaGen Therapeutics Inc.
Stock Symbol: VTGN
Market: NASDAQ
Website: vistagen.com
Menu
VTGN VTGN Quote VTGN Short VTGN News VTGN Articles VTGN Message Board
Get VTGN Alerts

News, Short Squeeze, Breakout and More Instantly...
VTGN - Biotech Industry Focusing on Growing Demand for Lyophilized Injectable Drugs

December 10, 2019 Palm Beach, FL –December 10, 2019 – There are so many paths that R&D is taking in the ongoing fight against cancer. New drugs, new therapies and new techniques are developed to help researchers and practitioners across all cancer sub-markets. One su...
VTGN - U.S. FDA Grants VistaGen Therapeutics Fast Track Designation for PH94B for Treatment of Social Anxiety Disorder

SOUTH SAN FRANCISCO, Calif. , Dec. 10, 2019 /PRNewswire/ --  VistaGen Therapeutics, Inc.  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, today announced ...

VTGN - IGT, OPRA, PING and SINA among midday movers

Gainers:  Astrotech Corporation (NASDAQ: ASTC ) +87% . More news on: Astrotech Corporation, Pier 1 Imports, Inc., Celsion Corporation, Stocks on the move, Read more ...

VTGN - VistaGen's AV-101 flunks MDD study; shares down 67%

Thinly traded nano cap VistaGen Therapeutics ( VTGN -67% ) craters on more than a 9x surge in volume after AV-101 failed to separate from placebo in a Phase 2 clinical trial, ELEVATE , evaluating the candidate for the adjunctive treatment of major depressive disorder. More news on: Vi...
VTGN - WB, CGC among premarket losers

VistaGen Therapeutics (NASDAQ: VTGN ) -67%  on reporting Phase 2 results for AV-101 as a treatment of major depressive disorder. More news on: VistaGen Therapeutics, Inc., Pacific Coast Oil Trust, Ideanomics, Inc., Stocks on the move, Read more ...

VTGN - VistaGen Reports Topline Phase 2 Results for AV-101 as an Adjunctive Treatment of Major Depressive Disorder

SOUTH SAN FRANCISCO, Calif. , Nov. 14, 2019 /PRNewswire/ --  VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, today announced topline res...

VTGN - VistaGen Therapeutics Reports Fiscal 2020 Second Quarter Financial Results and Provides Pipeline Overview

SOUTH SAN FRANCISCO, Calif. , Nov. 7, 2019 /PRNewswire/ --  VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, today announced financial re...
VTGN - VistaGen Therapeutics: PH10's Approval Potential Just Can't Outweigh Stock Dilution Risk

Company Thesis VistaGen Therapeutics (VTGN) is a small-cap biotech company currently possessing 3 drug candidates in clinical trials for various psychiatric indications. Out of the 3 candidates, both PH94B indicated for social anxiety disorder and AV-101 indicated for major depressive di...

VTGN - VistaGen Therapeutics Expands European Patent Protection for AV-101 for Treatment of Depression and Dyskinesia associated with Levodopa Therapy for Parkinson's Disease

SOUTH SAN FRANCISCO, Calif. , Oct. 28, 2019 /PRNewswire/ --  VistaGen Therapeutics  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, today announced that t...

VTGN - Axsome Therapeutics: Sizable Sales Upside From A Promising Trial Demands A Premium

Investment Thesis Backed by positive results from a phase 02 trial for Major Depressive Disorder ((MDD)), the shares of Axsome Therapeutics, Inc. ( AXSM ) have jumped nearly seven times in 2019 so far. Out of the six clinical trials currently in progress, four data readouts will be availab...
Previous 10 Next 10